Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Published Date: 19 Oct 2026

Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations

Read Full News

Latest News

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

CHEST 2026 Preview: Late-Breakers to Watch Out For

CHEST 2026 Preview: Late-Breakers to Watch Out For

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Todays Updates

Verekitug's Quarterly Dosing Cuts Asthma Burden, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Latest News

Biologic Access in Asthma and COPD: Clinical Forum Perspectives

Treatable Traits in Asthma and COPD: Clinical Forum Perspectives

Clinical Forum Weighs in: Biologic Selection in Asthma and COPD

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

CHEST 2026 Preview: Late-Breakers to Watch Out For

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

News All Time

Why Doctors Need to Complete the COPD or Asthma Workup to Rule Out Alpha-1 Kyle Hogarth, MD

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Childhood Pollution Exposure May Trigger COPD Polygenic Risk Victoria Johnson

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Ralinepag Improves Clinical Outcomes in Contemporary PAH Population Victoria Johnson

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

Q&A: PERFORM Data Support Triple Therapy in Milder Uncontrolled Asthma John Oppenheimer, MD

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

Zumilokibart Rapidly Suppresses FeNO in Phase 1b Asthma Data: Mario Castro, MD Mario Castro, MD, MPH

Castro, of University of Kansas discusses interim phase 1b data showing rapid, durable suppression in patients with mild to moderate asthma.

GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF Victoria Johnson

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

Dell discusses an analysis of VOYAGE showing dupilumab more than doubled the odds of favorable asthma outcomes in children, regardless of baseline ICS dose.

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

Olivier Sitbon, MD, PhD, reviews PDGF-targeted therapy in PAH, from imatinib's IMPRES trial to new prodrug and antibody approaches.

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

Recommended News For You

Top 10 questions about breast cancer answered

Smart exercise planning could boost recovery for people with cancer

Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Recommended Articles For You

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Comprehensive Breakthroughs in Oncology for Better Care 

The Different Types of Cysts and Why They Occur: Insights from a Dermatologist  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD

2.

How the skin cancer virus outperforms the replication of host cells.

3.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

4.

Housing aid linked to lower medical financial hardship among US renters with cancer

5.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

1.

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment

2.

Intensive Care Challenges in Advanced Cancer

3.

Childhood Cancer Survivorship and Long-Term Organ Health

4.

Guideline Evolution in Benign Hematologic Conditions

5.

The Latest Research on Wiskott Aldrich Syndrome 

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

3.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

5.

Navigating the Complexities of Ph Negative ALL - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot